BeStock  

BioCryst Pharmaceuticals BCRX

US equityMarket cap rank #2720Drug Manufacturers - Specialty & Generic
$7.22 −$0.10 (-1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.10 -1.66%
Open$7.26
Prev close$7.32
Day range$7.15 – $7.39
Volume3.85M
Market cap$1.86B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$180.29M+13.1% YoY
Operating profit$53.33M+80.2% YoY
Net profit$37.92M+193.9% YoY
Diluted EPS$0.14+133.3% YoY
Free cash flow$32.75M-18.7% YoY
Operating cash flow$32.98M

Revenue, last 8 quarters

$131.5MDec '24$145.5MMar '25$163.4MJun '25$159.4MSep '25$406.6MDec '25$156.4MMar '26$218.3MJun '26$180.3MSep '26

Net profit, last 8 quarters

$-26.8MDec '24$32.0KMar '25$5.1MJun '25$12.9MSep '25$245.8MDec '25$-721.8MMar '26$78.4MJun '26$37.9MSep '26

Diluted EPS by quarter

-0.13Dec '240.00Mar '250.02Jun '250.06Sep '251.12Dec '25-2.98Mar '260.30Jun '260.14Sep '26

Free cash flow by quarter

$-5.9MDec '24$-27.7MMar '25$41.1MJun '25$40.3MSep '25$291.2MDec '25$-62.2MMar '26$104.1MJun '26$32.8MSep '26

Annual revenue

$17.8MFY20$157.2MFY21$270.8MFY22$331.4MFY23$450.7MFY24$874.8MFY25

Profitability & balance sheet

Gross margin97.9%
Operating margin42.5%
Net margin-37.4%
Return on assets-69.3%
Current ratio2.71
Liabilities / assets167.2%
Cash & investments$375.00M
Total debt$781.01M
Net cash (debt)-$406.01M
Free cash flow / sales38.0%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $180.29M $218.25M $156.41M $874.84M $406.56M
Total Operating Revenue $180.29M $218.25M $156.41M $874.84M $406.56M
Cost of Revenue $1.57M $3.84M $5.38M $19.08M $9.52M
Gross Profit $178.72M $214.41M $151.04M $855.76M $397.03M
Operating Expense $125.39M $115.95M $154.87M $514.77M $136.65M
Selling and Admin Expenses $67.18M $63.98M $94.55M $348.65M $95.78M
Research & Development $58.21M $51.97M $60.32M $166.13M $40.87M
Operating Profit $53.33M $98.47M -$3.84M $340.99M $260.39M
Net Non-Operating Interest Income (Expense) -$18.11M -$19.28M -$17.52M -$68.20M -$11.25M
Non-Operating Interest Income $3.07M $2.43M $2.26M $10.67M $2.89M
Non-Operating Interest Expense $21.19M $21.71M $19.78M $78.87M $14.14M
Other Income (Expense) $3.37M $287,000.00 -$699.45M -$5.39M -$1.12M
Gain on Sale of Security $22,000.00 $27,000.00 -$225,000.00 -$152,000.00 -$125,000.00
Special Income (Charges) $0.00 $0.00 -$697.76M -$17.33M -$10.42M
Other Non-Operating Income (Expenses) $3.35M $260,000.00 -$1.46M $12.09M $9.42M
Pretax Profit $38.59M $79.47M -$720.81M $267.39M $248.02M
Tax $669,000.00 $1.08M $1.00M $3.53M $2.17M
Net Profit $37.92M $78.40M -$721.81M $263.86M $245.85M
Profit from Continuing Operations $37.92M $78.40M -$721.81M $263.86M $245.85M
Net Income to Parent Company $37.92M $78.40M -$721.81M $263.86M $245.85M
Net Income to Common Stockholders $37.92M $78.40M -$721.81M $263.86M $245.85M
Basic EPS $0.15 $0.31 -$2.98 $1.26 $1.17
Diluted EPS $0.14 $0.30 -$2.98 $1.21 $1.12
-Less:Other Special Charges – – $697.76M $17.33M $10.42M

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $591.07M $557.85M $465.05M $514.16M $514.16M
Total Current Assets $531.15M $484.68M $373.63M $404.35M $404.35M
Cash and Cash Equivalents & Short-Term Investments $375.00M $352.57M $238.40M $274.75M $274.75M
-Cash and Cash Equivalents $96.97M $154.97M $171.59M $89.74M $89.74M
-Short Term Investments $278.03M $197.60M $66.81M $185.01M $185.01M
Receivables $121.79M $110.76M $109.27M $106.82M $106.82M
-Accounts Receivable $121.79M $110.76M $109.27M $106.82M $106.82M
Inventory $13.74M $6.06M $5.99M $5.40M $5.40M
Restricted Cash $518,000.00 $479,000.00 $854,000.00 $201,000.00 $201,000.00
Other Current Assets $20.11M $14.82M $19.11M $17.18M $17.18M
Total Non-Current Assets $59.92M $73.17M $91.43M $109.81M $109.81M
Net PPE $7.48M $21.67M $22.99M $18.99M $18.99M
-Gross PPE $7.48M $21.67M $22.99M $28.38M $28.38M
Investments and Advances $0.00 $0.00 $20.57M $61.16M $61.16M
Other Non-Current Assets $52.44M $51.50M $47.87M $29.66M $29.66M
Total Liabilities $988.45M $1.01B $1.02B $633.31M $633.31M
Total Current Liabilities $195.83M $208.85M $195.39M $196.07M $196.07M
Payables $14.58M $11.46M $10.96M $24.79M $24.79M
-Accounts Payable $14.58M $11.46M $10.96M $15.83M $15.83M
Current Accrued Expenses $110.69M $121.90M $119.40M $39.96M $39.96M
Short-Term Debt and Capital Lease Obligation $3.44M $3.00M $3.09M $1.63M $1.63M
-Current Capital Lease Obligation $3.44M $3.00M $3.09M $1.63M $1.63M
Current Deferred Liabilities $10.54M $12.32M $5.41M – –
Other Current Liabilities $56.58M $60.17M $56.53M $52.20M $52.20M
Total Non-Current Liabilities $792.62M $803.29M $823.50M $437.25M $437.25M
Long Term Debt and Capital Lease Obligation $781.01M $789.83M $814.67M $437.25M $437.25M
-Long Term Debt $773.55M $778.38M $802.38M $427.23M $427.23M
-Long Term Capital Lease Obligation $7.46M $11.45M $12.30M $10.01M $10.01M
Non-Current Deferred Liabilities $11.61M $13.46M $8.83M – –
Total Equity -$397.38M -$454.29M -$553.84M -$119.15M -$119.15M
Stockholders' Equity -$397.38M -$454.29M -$553.84M -$119.15M -$119.15M
Capital Stock $2.56M $2.55M $2.54M $2.13M $2.13M
-Common Stock $2.56M $2.55M $2.54M $2.13M $2.13M
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.71B $1.69B $1.67B $1.38B $1.38B
Retained Earnings -$2.11B -$2.15B -$2.23B -$1.51B -$1.51B
Gains/Losses Not Affecting Retained Earnings -$607,000.00 -$528,000.00 -$368,000.00 $38,000.00 $38,000.00
-Accumulated Depreciation – – – -$9.39M -$9.39M
-Other Payable – – – $8.96M $8.96M
Current Provisions – – – $26.63M $26.63M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $32.98M $104.34M -$61.79M $347.37M $291.96M
Net cash flow from continuing operations $32.98M $104.34M -$61.79M $347.37M $291.96M
Net Income from Continuing Operations $37.92M $78.40M -$721.81M $263.86M $245.85M
Gain/Loss from Continuing Operations -$2.89M $524,000.00 $2.81M $26.45M $20.09M
Depreciation & Depletion & Amortization $244,000.00 $513,000.00 $461,000.00 $1.39M $394,000.00
Other Non-Cash Items $11.97M $13.75M $711.88M $30.85M -$1.23M
Change in Working Capital -$36.66M -$3.11M -$71.40M -$56.90M $4.23M
-Change in Receivables -$11.03M -$1.49M -$474,000.00 -$36.81M -$15.49M
-Change in Inventory -$6.87M -$4.35M -$4.85M -$1.64M -$515,000.00
-Change in Prepaid Assets -$5.92M $4.43M $3.53M -$7.83M -$1.94M
-Change in Payables and Accrued Expense $9.66M $5.07M -$60.40M $57.80M $35.36M
-Change in Other Current Liabilities -$18.86M -$18.32M -$8.47M -$68.43M -$13.19M
-Change In Other Working Capital -$3.63M $11.54M -$749,000.00 – –
Net cash flow from investing -$78.88M -$110.15M -$268.65M -$13.69M -$83.49M
Net Cash Flow from Continuing Investing Activities -$78.88M -$110.15M -$268.65M -$13.69M -$83.49M
Net PPE Purchase and Sale -$166,000.00 -$209,000.00 -$403,000.00 -$2.47M -$802,000.00
Net Business Purchase and Sale $0.00 $0.00 -$489.48M -$6.18M -$6.18M
Net Investment Purchase and Sale -$78.71M -$109.94M $221.24M -$5.59M -$76.50M
Financing Cash Flow -$12.08M -$11.15M $412.55M -$349.93M -$217.96M
Net Cash Flow from Continuing Financing Activities -$12.08M -$11.15M $412.55M -$349.93M -$217.96M
Net Issuance Payments Of Debt -$5.25M -$361,000.00 $399.66M -$301.99M -$184.58M
Net Common Stock Issuance $49,000.00 $44,000.00 $33,000.00 $59,000.00 $23,000.00
Proceeds from Stock Option Exercised $4.24M $6.20M $19.48M $9.12M $657,000.00
Net Other Financing Charges -$11.12M -$17.04M -$6.62M -$57.12M -$34.06M
Ending Cash Balance $98.42M $156.38M $173.38M $91.34M $91.34M
Net Change in Cash -$57.97M -$16.96M $82.11M -$16.26M -$9.49M
Beginning Cash Balance $156.38M $173.38M $91.34M $106.32M $86.06M
Effect of Exchange Rate Changes $6,000.00 -$35,000.00 -$72,000.00 $1.27M -$72,000.00
Free Cash Flow $32.75M $104.13M -$62.19M $344.90M $291.16M
Net Other Investing Changes – – – $550,000.00 $0.00

Discussion

No comments yet — be the first to weigh in on BCRX.

Sign in to join the discussion.

Scroll to Top